Search Results - "Thomassen, M. Christella L. G. D"

Activated protein C resistance determined with a thrombin generation‐based test predicts for venous thrombosis in men and women by Tans, Guido, Van Hylckama Vlieg, Astrid, Thomassen, M. Christella L. G. D., Curvers, Joyce, Bertina, Rogier M., Rosing, Jan, Rosendaal, Frits R.

“…Activated protein C (APC) resistance, determined with a thrombin‐generation‐based APC resistance test, may explain risk differences of venous thrombosis in…”
Get full text

Severe thrombophilia in a factor V‐deficient patient homozygous for the Ala2086Asp mutation (FV Besançon) by Castoldi, Elisabetta, Hézard, Nathalie, Mourey, Guillaume, Wichapong, Kanin, Poggi, Marjorie, Ibrahim‐Kosta, Manal, Thomassen, M. Christella L. G. D., Fournel, Alexandra, Hayward, Catherine P. M., Alessi, Marie‐Christine, Hackeng, Tilman M., Rosing, Jan, Morange, Pierre‐Emmanuel

“…Background Coagulation factor V (FV), present in plasma and platelets, has both pro‐ and anticoagulant functions. Objective We investigated an FV‐deficient…”
Get full text

Segregation of Platelet Aggregatory and Procoagulant Microdomains in Thrombus Formation: Regulation by Transient Integrin Activation by Munnix, Imke C.A, Kuijpers, Marijke J.E, Auger, Jocelyn, Thomassen, Christella M.L.G.D, Panizzi, Peter, van Zandvoort, Marc A.M, Rosing, Jan, Bock, Paul E, Watson, Steve P, Heemskerk, Johan W.M

“…OBJECTIVE—Platelets play a dual role in thrombosis by forming aggregates and stimulating coagulation. We investigated the commitment of platelets to these…”
Get full text

Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation by Maurissen, Lisbeth F.A., Thomassen, M. Christella L. G.D., Nicolaes, Gerry A.F., Dahlbäck, Björn, Tans, Guido, Rosing, Jan, Hackeng, Tilman M.

“…Protein S expresses cofactor activity for activated protein C (APC) by enhancing the APC-catalyzed proteolysis at R306 in factor Va. It is generally accepted…”
Get full text

Incorporation of Disulfide Containing Protein Modules into Multivalent Antigenic Conjugates: Generation of Antibodies against the Thrombin-Sensitive Region of Murine Protein S by Van de Vijver, Pieter, Schmitt, Martin, Suylen, Dennis, Scheer, Liesbeth, Thomassen, M. Christella L. G. D, Schurgers, Leon J, Griffin, John H, Koenen, Rory R, Hackeng, Tilman M

“…Antigenic peptide conjugates can be used as vaccines and for the production of antibodies for clinical and research use. A method is presented here for the…”
Get full text

Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography by Tchaikovski, Svetlana N, van Vliet, Huib A A M, Thomassen, M C L G D, Bertina, Rogier M, Rosendaal, Frits R, Sandset, Per-Morten, Helmerhorst, Frans M, Tans, Guido, Rosing, Jan

“…In a study population consisting of healthy men (n = 8), women not using oral contraceptives (OC) (n = 28) and women using different kinds of OC (n = 187) we…”
Get more information

Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test by Curvers, Joyce, Thomassen, M Christella L G D, Rimmer, Janet, Hamulyak, Karly, van der Meer, Jan, Tans, Guido, Preston, F Eric, Rosing, Jan

“…Several hereditary and acquired risk factors for venous thromboembolism (VTE) are associated with impaired down-regulation of thrombin formation via the…”
Get more information

Protein arginine deiminase 4 inactivates tissue factor pathway inhibitor-alpha by enzymatic modification of functional arginine residues by Thomassen, M. Christella L.G.D., Bouwens, Bryan R.C., Wichapong, Kanin, Suylen, Dennis P., Bouwman, Freek G., Hackeng, Tilman M., Koenen, Rory R.

“…Tissue factor pathway inhibitor (TFPI) is an important regulator of coagulation and a link between inflammation and thrombosis. During thrombotic events, TFPI…”
Get full text

Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women by Hemelaar, Majoie, Rosing, Jan, Kenemans, Peter, Thomassen, M Christella L.G.D, Braat, Didi D.M, van der Mooren, Marius J

“…OBJECTIVE—To compare the effects of intranasal and oral administration of 17β-estradiol (E2) and norethisterone(acetate) [NET(A)] in healthy postmenopausal…”
Get full text

Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI) by Dockal, Michael, Hartmann, Rudolf, Fries, Markus, Thomassen, M Christella L G D, Heinzmann, Alexandra, Ehrlich, Hartmut, Rosing, Jan, Osterkamp, Frank, Polakowski, Thomas, Reineke, Ulrich, Griessner, Andreas, Brandstetter, Hans, Scheiflinger, Friedrich

“…Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor that inhibits activated factor X (FXa) via a slow-tight binding mechanism and tissue…”
Get full text

Acquired APC resistance and oral contraceptives: differences between two functional tests by Curvers, Joyce, Thomassen, M. Christella L. G. D., Nicolaes, Gerry A. F., Van Oerle, Rene, Hamulyak, Karly, Coenraad HEMKER, H., Tans, Guido, Rosing, Jan

“…Resistance to activated protein C (APC) is often associated with a mutation in factor V (factor VLeiden). Individuals without factor VLeiden who exhibit a…”
Get full text

Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia by Tchaikovski, S N, Thomassen, M C L G D, Costa, S-D, Peeters, L L H, Rosing, J

“…Pregnancy increases the risk of venous thromboembolism. Particularly in early pregnancy, the thrombosis risk can be attributed to the changes in coagulation…”
Get more information

Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool by Christella, M, Thomassen, LG, Castoldi, E, Tans, G, Magdeleyns, EJ, Delaunoit, C, Debusscher, L, Van Assche, KJ, Rosing, J

“…Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands. BACKGROUND AND OBJECTIVES:…”
Get full text

Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies by Duschek, Erik JJ, Neele, Simone J, Thomassen, M Christella LGD, Rosing, Jan, Netelenbos, Coen

“…Raloxifene, a selective estrogen receptor modulator, like hormonal replacement therapy increases the risk of venous thromboembolism in postmenopausal women. A…”
Get full text

Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis: A Randomized, Placebo-Controlled Study in Postmenopausal Women by Post, Marinka S, Christella, M, Thomassen, L.G.D, van der Mooren, Marius J, van Baal, W Marchien, Rosing, Jan, Kenemans, Peter, Stehouwer, Coen D.A

“…OBJECTIVE—The purpose of this study was to investigate whether the effect of transdermal estrogen therapy in postmenopausal women differs from that of oral…”
Get full text

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study by Rosing, Jan, Middeldorp, Saskia, Curvers, Joyce, Thomassen, M Christella L GDlig, Nicolaes, Gerry AF, Meijers, Joost CM, Bouma, Bonno N, Büller, Harry R, Prins, Martin H, Tans, Guido

“…We have reported previously that, compared with use of second-generation oral contraceptives, the use of third-generation oral contraceptives is associated…”
Get full text

Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens by van Vliet, Huib A.A.M., Frolich, Marijke, Christella, M., Thomassen, L.G.D., Doggen, Carine J.M., Rosendaal, Frits R., Rosing, Jan, Helmerhorst, Frans M.

“…BACKGROUND: Epidemiological studies have shown that both the estrogen dose and progestogen type of oral contraceptives contribute to the increased risk of…”
Get full text

A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways by Tans, G, Curvers, J, Middeldorp, S, Thomassen, M C, Meijers, J C, Prins, M H, Bouma, B N, Büller, H R, Rosing, J

“…The use of oral contraceptives (OC) causes disturbances of the procoagulant, anticoagulant and fibrinolytic pathways of blood coagulation which may contribute…”
Get more information

Effect of oral contraceptives on the anticoagulant activity of protein S in plasma by Koenen, Rory R, Christella, M, Thomassen, L G D, Tans, Guido, Rosing, Jan, Hackeng, Tilman M

“…We determined anticoagulant parameters that depend on protein S function in plasma, i.e. the APC-independent anticoagulant activity of protein S (expressed as…”
Get more information

Peptide Bond Cleavages and Loss of Functional Activity during Inactivation of Factor Va and Factor Va by Activated Protein C by Gerry A. F. Nicolaes, Guido Tans, M. Christella L. G. D. Thomassen, H. Coenraad Hemker, Ingrid Pabinger, Katalin Varadi, Hans P. Schwarz, Jan Rosing

“…Factor V was purified from the plasma of an activated protein C (APC)-resistant patient who is homozygous for the mutation Arg Gln (factor V ). Factor V was…”
Get full text